~BSSP .0001 News Alert...
Reve Acquires Exclusive License for Canteck's IPF Irreversable Pepsin Fraction Specific to Cancer Indication Only for Mexico
Embarks on Shift to Immunotherapeutic IPF Platform Technology for Development, Manufacture and Commercialization
SAN CLEMENTE CA / ACCESSWIRE / April 25, 2016 / Reve Technologies, Inc. (OTCPK: BSSP) (the "Company" or "Reve") a development stage technology company is pleased to announce entered into a Purchase and Sale Agreement (the "Purchase Agreement") with Canteck Pharma, Inc., a Delaware corporation ("Canteck" or "CKPH") and certain majority shareholders of CKPH. Canteck has developed and patented technology (US 8,067,531 B2) known as Irreversible Pepsin Fraction ("IPF"). IPF is a therapeutic platform technology that can be used to facilitate a broad range of applications. It is free from neurological, gastrointestinal and hematological side effects. IPF has not shown to be subject to viral resistance and is cost effective.
The Purchase Agreement sets forth the plan through which the Company acquires One Hundred Percent (100%) ownership Interest in Canteck Pharma, Inc. for its current and planned operations in Mexico through the exclusive Sub Licensing Agreement for Irreversible Pepsin Fraction specific to the Cancer indication only;
As part of the Agreement with Canteck, the Company, and majority shareholders of both Canteck and Reve, approved a change of control by appointing Mrs. Diana Zhabilov, who has extensive medial based qualifications and certifications as Chairman and President, (director) and Mr. Harry Zhabilov Jr. BSc, McS Science as Chief Scientist of the Company. Mr. Zhabilov is responsible for development of the Patented Technology and various applications including the platform for the Irreversible Pepsin Fraction specific to the Cancer indication. Mr. Dennis Alexander continues as Chief Executive Offer and Director, and Ms. Joanne M. Sylvanus continues as Chief Financial Officer, Secretary and Director. It was further agreed that Valentine Dimitrov is to be appointed to the Board of Directors after the closing of the Purchase Agreement as a fifth Director.
The initial deployment for sales of the specific IPF for Cancer indication product and treatment programs to Mexico are now in process with four hospitals positioned and in process of licensing requirements which have been submitted. Canteck is positioned to oversee the development, manufacturing and commercialization processes for our lead product to be the Irreversible Pepsin Fraction (IPF) specific to the Cancer indication, with options for other indications.
"Our transition to the corporate platform for development and deployment of targeted therapeutic immunotherapeutic technology represents an important event in our transition and growth," said Dennis Alexander, CEO of the Company. "Further, the Company welcomes our current and future development with Canteck Pharma, Inc., and working together with our new Board of Directors and Management including Mr. and Mrs. Zhabilov, as the Company looks forward to bringing these novel technological advancements to the forefront initially to Mexico to assist treatment and solutions for specific Cancer treatment and to become available in a cost effective manner to assist the severity of medical needs going unmet."
"The licensing agreement with Reve Technologies, Inc. is very much an important milestone in our goal to develop and commercialize our immune-oncology based IPF treatment as a new therapy for difficult-to-treat tumor indications on a scalable international level initially in Mexico." Said Mr. Harry Zhabilov, Jr. BSc, McS and newly appointed Chief Sciencist of the Company. "We are delighted to have a committed partner and management team and with our missions aligned and look forward to working together to obtain approvals for our IPF Irreversible Pepsin Fraction specific to the Cancer indication, and to bring these much-needed therapeutic options as soon as possible for delivery and availability to Mexico."
About Canteck Pharma, Inc. IPF for Cancer treatment
Immunotherapy has the potential to provide an alternative and/or complementary treatment for most types of cancer. The advantage of immunotherapy over radiation and chemotherapy is that it can act specifically against the tumor without causing normal tissue damage. Current data indicates that immune protection against all cancer requires the generation of a potent cellular immune response against a unique tumor antigen expressed by the malignant cell. As a consequence successful immune protection first requires a unique antigen expressed in the tumor cells (tumor specific antigen) and second, an induction of a potent T-cell immune response, targeted to the tumor antigen.
Unfortunately the immune system by itself can't recognize specific tumor antigens and reject them; however recent advances have revealed that certain proteins binding with specific tumor antigens can be recognized by the immune system, this is what IPF does.
IPF proteins attach to tumor antigens, creating superantigens (Sags), which increases the number of antibodies against the malignant cells and induces a potent T-cell immune response targeted to the tumor antigen. For a stronger immune response, IPF may be paired with different kinds of adjuvants such as IL-2, IL-6, IL-12 or other cytokines. Another form of immunotherapy can also provide active immunization, which allows for amplification of the immune response. In addition, vaccines can generate a memory immune response. Recent advances have revealed that any cellular protein (expressed in virally infected cells or cancer cells) can be recognized by the immune system if those proteins are presented to the immune system in a form that results in an activation rather than ignorance or tolerance to the antigen. In addition, T-cells rather than B-cells are usually responsible for this recognition.
It is important to point out that when we discuss vaccines for cancer we are referring to treatment rather than prevention, because the antigens expressed by tumor cells (which are the immunogens recognized by the immune system) are not yet known. Attaching known proteins will increase the number of antibodies to fight against them.
This mechanism of action will give us an exact answer (known antigens we have to make known for immune system). In contrast we can use vaccines to prevent infectious diseases because the antigens expressed the causative agent - fraction and/or its proteins that can attach, serve as the immunogen are already known.
About Reve Technologies, Inc.
The Company was incorporated on May 11, 2010 (Date of Inception) under the laws of the State of Nevada, as Bassline Productions, Inc. On March 21, 2014 the Company amended its articles of incorporation and changed its name to Reve Technologies, Inc. and investing to develop and market emerging hardware, mobile and web applications later establishing a new Capital Purchase Division. The Company is now a transitioning forward with the acquisition of an Exclusive License Agreement for Patented Technology for Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico with privately held immune-oncology and Therapeutics company. Through the terms for the Company's Exclusive Sub Licensing Agreement with Canteck Pharma, Inc. we will focus on the development, manufacture and commercialize our lead product Irreversible Pepsin Fraction (IPF) specific to the Cancer indication only, for Mexico, with options for other indications.
This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Reve Technologies, Inc., its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Reve Technologies, Inc.'s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Reve Technologies, Inc.'s filings with the Securities and Exchange Commission.
Public Relations and Shareholder
Name: Dennis Alexander
Phone: (602) 326-7371
SOURCE: Reve Technologies, Inc.
© Copyright © 2016 Accesswire. All rights reserved.